Does the media favor INDV or MPLT?

In the previous week, Maplight Therapeutics had 9 more articles in the media than Indivior. MarketBeat recorded 11 mentions for Maplight Therapeutics and 2 mentions for Indivior. Indivior's average media sentiment score of 0.72 beat Maplight Therapeutics' score of 0.41 indicating that Indivior is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Indivior 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Maplight Therapeutics 1 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has stronger earnings and valuation, ERAS or MPLT?

Erasca is trading at a lower price-to-earnings ratio than Maplight Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Erasca N/A N/A -$124.55M -$0.93 N/A Maplight Therapeutics N/A N/A -$161.15M -$40.99 N/A

Is ERAS or MPLT more profitable?

Maplight Therapeutics' return on equity of 0.00% beat Erasca's return on equity. Company Net Margins Return on Equity Return on Assets Erasca N/A -35.31% -29.49% Maplight Therapeutics N/A N/A N/A

Does the media prefer ERAS or MPLT?

In the previous week, Erasca had 23 more articles in the media than Maplight Therapeutics. MarketBeat recorded 34 mentions for Erasca and 11 mentions for Maplight Therapeutics. Maplight Therapeutics' average media sentiment score of 0.41 beat Erasca's score of 0.08 indicating that Maplight Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Erasca 2 Very Positive mention(s) 3 Positive mention(s) 26 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Maplight Therapeutics 1 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has stronger valuation and earnings, MPLT or EWTX?

Edgewise Therapeutics is trading at a lower price-to-earnings ratio than Maplight Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Maplight Therapeutics N/A N/A -$161.15M -$40.99 N/A Edgewise Therapeutics N/A N/A -$167.79M -$1.66 N/A

Is MPLT or EWTX more profitable?

Maplight Therapeutics' return on equity of 0.00% beat Edgewise Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Maplight Therapeutics N/A N/A N/A Edgewise Therapeutics N/A -32.55% -31.04%

Does the media prefer MPLT or EWTX?

In the previous week, Maplight Therapeutics had 9 more articles in the media than Edgewise Therapeutics. MarketBeat recorded 11 mentions for Maplight Therapeutics and 2 mentions for Edgewise Therapeutics. Edgewise Therapeutics' average media sentiment score of 1.50 beat Maplight Therapeutics' score of 0.41 indicating that Edgewise Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Maplight Therapeutics 1 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Neutral Edgewise Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Maplight Therapeutics (MPLT) Competitors

$33.28 0.00 (0.00%)

Closing price 06/26/2026 04:00 PM Eastern

Extended Trading

$32.34 -0.94 (-2.84%)

As of 06/26/2026 05:18 PM Eastern

Compare

MPLT vs. INDV, DNTH, ERAS, KNSA, and EWTX

Should you buy Maplight Therapeutics stock or one of its competitors? MarketBeat compares Maplight Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Maplight Therapeutics include Indivior (INDV), Dianthus Therapeutics (DNTH), Erasca (ERAS), Kiniksa Pharmaceuticals International (KNSA), and Edgewise Therapeutics (EWTX). These companies are all part of the "pharmaceutical products" industry.

How does Maplight Therapeutics compare to Indivior?

Indivior (NASDAQ:INDV) and Maplight Therapeutics (NASDAQ:MPLT) are both pharmaceutical products companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, profitability, valuation, analyst recommendations, dividends, earnings, media sentiment and risk.

60.3% of Indivior shares are owned by institutional investors. 0.7% of Indivior shares are owned by company insiders. Comparatively, 3.8% of Maplight Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Indivior currently has a consensus target price of $40.29, indicating a potential downside of 3.69%. Maplight Therapeutics has a consensus target price of $38.80, indicating a potential upside of 16.59%. Given Maplight Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Maplight Therapeutics is more favorable than Indivior.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Indivior	0 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	3.00
Maplight Therapeutics	1 Sell rating(s)	1 Hold rating(s)	9 Buy rating(s)	4 Strong Buy rating(s)	3.07

In the previous week, Maplight Therapeutics had 9 more articles in the media than Indivior. MarketBeat recorded 11 mentions for Maplight Therapeutics and 2 mentions for Indivior. Indivior's average media sentiment score of 0.72 beat Maplight Therapeutics' score of 0.41 indicating that Indivior is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Indivior	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Maplight Therapeutics	1 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral

Indivior has higher revenue and earnings than Maplight Therapeutics. Maplight Therapeutics is trading at a lower price-to-earnings ratio than Indivior, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Indivior	$1.24B	4.12	$210M	$1.95	21.45
Maplight Therapeutics	N/A	N/A	-$161.15M	-$40.99	N/A

Indivior has a net margin of 19.44% compared to Maplight Therapeutics' net margin of 0.00%. Maplight Therapeutics' return on equity of 0.00% beat Indivior's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Indivior	19.44%	-219.26%	29.40%
Maplight Therapeutics	N/A	N/A	N/A

Summary

Indivior beats Maplight Therapeutics on 8 of the 15 factors compared between the two stocks.

How does Maplight Therapeutics compare to Dianthus Therapeutics?

Maplight Therapeutics (NASDAQ:MPLT) and Dianthus Therapeutics (NASDAQ:DNTH) are both pharmaceutical products companies, but which is the better business? We will compare the two businesses based on the strength of their analyst recommendations, dividends, valuation, risk, profitability, media sentiment, institutional ownership and earnings.

Maplight Therapeutics has higher earnings, but lower revenue than Dianthus Therapeutics. Dianthus Therapeutics is trading at a lower price-to-earnings ratio than Maplight Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Maplight Therapeutics	N/A	N/A	-$161.15M	-$40.99	N/A
Dianthus Therapeutics	$2.04M	2,555.29	-$162.34M	-$4.13	N/A

Maplight Therapeutics has a net margin of 0.00% compared to Dianthus Therapeutics' net margin of -12,998.50%. Maplight Therapeutics' return on equity of 0.00% beat Dianthus Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Maplight Therapeutics	N/A	N/A	N/A
Dianthus Therapeutics	-12,998.50%	-27.30%	-25.91%

Maplight Therapeutics currently has a consensus target price of $38.80, indicating a potential upside of 16.59%. Dianthus Therapeutics has a consensus target price of $117.82, indicating a potential upside of 23.56%. Given Dianthus Therapeutics' higher possible upside, analysts clearly believe Dianthus Therapeutics is more favorable than Maplight Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Maplight Therapeutics	1 Sell rating(s)	1 Hold rating(s)	9 Buy rating(s)	4 Strong Buy rating(s)	3.07
Dianthus Therapeutics	1 Sell rating(s)	0 Hold rating(s)	12 Buy rating(s)	1 Strong Buy rating(s)	2.93

47.5% of Dianthus Therapeutics shares are owned by institutional investors. 3.8% of Maplight Therapeutics shares are owned by insiders. Comparatively, 3.0% of Dianthus Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

In the previous week, Maplight Therapeutics had 10 more articles in the media than Dianthus Therapeutics. MarketBeat recorded 11 mentions for Maplight Therapeutics and 1 mentions for Dianthus Therapeutics. Dianthus Therapeutics' average media sentiment score of 1.89 beat Maplight Therapeutics' score of 0.41 indicating that Dianthus Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
Maplight Therapeutics	Neutral
Dianthus Therapeutics	Very Positive

Summary

Maplight Therapeutics beats Dianthus Therapeutics on 9 of the 15 factors compared between the two stocks.

How does Maplight Therapeutics compare to Erasca?

Erasca (NASDAQ:ERAS) and Maplight Therapeutics (NASDAQ:MPLT) are both pharmaceutical products companies, but which is the better stock? We will compare the two businesses based on the strength of their analyst recommendations, risk, earnings, institutional ownership, media sentiment, dividends, valuation and profitability.

67.8% of Erasca shares are held by institutional investors. 14.2% of Erasca shares are held by company insiders. Comparatively, 3.8% of Maplight Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

In the previous week, Erasca had 23 more articles in the media than Maplight Therapeutics. MarketBeat recorded 34 mentions for Erasca and 11 mentions for Maplight Therapeutics. Maplight Therapeutics' average media sentiment score of 0.41 beat Erasca's score of 0.08 indicating that Maplight Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Erasca	2 Very Positive mention(s)	3 Positive mention(s)	26 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Maplight Therapeutics	1 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral

Erasca presently has a consensus target price of $20.11, suggesting a potential upside of 25.50%. Maplight Therapeutics has a consensus target price of $38.80, suggesting a potential upside of 16.59%. Given Erasca's higher probable upside, analysts plainly believe Erasca is more favorable than Maplight Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Erasca	1 Sell rating(s)	2 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.60
Maplight Therapeutics	1 Sell rating(s)	1 Hold rating(s)	9 Buy rating(s)	4 Strong Buy rating(s)	3.07

Maplight Therapeutics' return on equity of 0.00% beat Erasca's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Erasca	N/A	-35.31%	-29.49%
Maplight Therapeutics	N/A	N/A	N/A

Erasca is trading at a lower price-to-earnings ratio than Maplight Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Erasca	N/A	N/A	-$124.55M	-$0.93	N/A
Maplight Therapeutics	N/A	N/A	-$161.15M	-$40.99	N/A

Summary

Maplight Therapeutics beats Erasca on 7 of the 13 factors compared between the two stocks.

How does Maplight Therapeutics compare to Kiniksa Pharmaceuticals International?

Maplight Therapeutics (NASDAQ:MPLT) and Kiniksa Pharmaceuticals International (NASDAQ:KNSA) are both pharmaceutical products companies, but which is the superior business? We will compare the two businesses based on the strength of their dividends, earnings, profitability, valuation, risk, media sentiment, analyst recommendations and institutional ownership.

Kiniksa Pharmaceuticals International has higher revenue and earnings than Maplight Therapeutics. Maplight Therapeutics is trading at a lower price-to-earnings ratio than Kiniksa Pharmaceuticals International, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Maplight Therapeutics	N/A	N/A	-$161.15M	-$40.99	N/A
Kiniksa Pharmaceuticals International	$677.56M	6.72	$59.01M	$0.90	65.78

54.0% of Kiniksa Pharmaceuticals International shares are owned by institutional investors. 3.8% of Maplight Therapeutics shares are owned by company insiders. Comparatively, 52.0% of Kiniksa Pharmaceuticals International shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Maplight Therapeutics currently has a consensus price target of $38.80, indicating a potential upside of 16.59%. Kiniksa Pharmaceuticals International has a consensus price target of $60.86, indicating a potential upside of 2.80%. Given Maplight Therapeutics' stronger consensus rating and higher probable upside, research analysts clearly believe Maplight Therapeutics is more favorable than Kiniksa Pharmaceuticals International.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Maplight Therapeutics	1 Sell rating(s)	1 Hold rating(s)	9 Buy rating(s)	4 Strong Buy rating(s)	3.07
Kiniksa Pharmaceuticals International	0 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	3.00

In the previous week, Maplight Therapeutics had 8 more articles in the media than Kiniksa Pharmaceuticals International. MarketBeat recorded 11 mentions for Maplight Therapeutics and 3 mentions for Kiniksa Pharmaceuticals International. Kiniksa Pharmaceuticals International's average media sentiment score of 1.29 beat Maplight Therapeutics' score of 0.41 indicating that Kiniksa Pharmaceuticals International is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Maplight Therapeutics	1 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral
Kiniksa Pharmaceuticals International	1 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Kiniksa Pharmaceuticals International has a net margin of 9.69% compared to Maplight Therapeutics' net margin of 0.00%. Kiniksa Pharmaceuticals International's return on equity of 13.26% beat Maplight Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Maplight Therapeutics	N/A	N/A	N/A
Kiniksa Pharmaceuticals International	9.69%	13.26%	9.86%

Summary

Kiniksa Pharmaceuticals International beats Maplight Therapeutics on 10 of the 15 factors compared between the two stocks.

How does Maplight Therapeutics compare to Edgewise Therapeutics?

Maplight Therapeutics (NASDAQ:MPLT) and Edgewise Therapeutics (NASDAQ:EWTX) are both pharmaceutical products companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, earnings, profitability, risk, analyst recommendations, dividends, valuation and institutional ownership.

In the previous week, Maplight Therapeutics had 9 more articles in the media than Edgewise Therapeutics. MarketBeat recorded 11 mentions for Maplight Therapeutics and 2 mentions for Edgewise Therapeutics. Edgewise Therapeutics' average media sentiment score of 1.50 beat Maplight Therapeutics' score of 0.41 indicating that Edgewise Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Maplight Therapeutics	1 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral
Edgewise Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

Maplight Therapeutics currently has a consensus target price of $38.80, indicating a potential upside of 16.59%. Edgewise Therapeutics has a consensus target price of $47.30, indicating a potential upside of 14.09%. Given Maplight Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Maplight Therapeutics is more favorable than Edgewise Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Maplight Therapeutics	1 Sell rating(s)	1 Hold rating(s)	9 Buy rating(s)	4 Strong Buy rating(s)	3.07
Edgewise Therapeutics	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.78

Maplight Therapeutics' return on equity of 0.00% beat Edgewise Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Maplight Therapeutics	N/A	N/A	N/A
Edgewise Therapeutics	N/A	-32.55%	-31.04%

Edgewise Therapeutics is trading at a lower price-to-earnings ratio than Maplight Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Maplight Therapeutics	N/A	N/A	-$161.15M	-$40.99	N/A
Edgewise Therapeutics	N/A	N/A	-$167.79M	-$1.66	N/A

Summary

Maplight Therapeutics beats Edgewise Therapeutics on 9 of the 11 factors compared between the two stocks.

Get Maplight Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding MPLT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

MPLT vs. The Competition

Export

Metric	Maplight Therapeutics	Industry	Manufacturing Sector	NASDAQ Exchange
Market Cap	$1.42B	$2.93B	$4.35B	$12.17B
Dividend Yield	N/A	15.33%	12.97%	6.11%
P/E Ratio	-0.81	13.53	22.01	24.17
Price / Sales	N/A	2,891.52	160.43	102.83
Price / Cash	N/A	26.38	36.62	36.93
Price / Book	3.30	5.14	13.62	6.38
Net Income	-$161.15M	-$34.63M	$113.19M	$337.00M
7 Day Performance	11.72%	-0.96%	-0.99%	-0.20%
1 Month Performance	13.54%	-1.88%	-3.43%	-1.40%
1 Year Performance	N/A	12.10%	11.94%	27.76%

Maplight Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
MPLT Maplight Therapeutics	3.0489 of 5 stars	$33.28 flat	$38.80 +16.6%	N/A	$1.42B	N/A	N/A	109	News Coverage Gap Down High Trading Volume
INDV Indivior	2.1451 of 5 stars	$41.47 +3.8%	$40.29 -2.9%	+199.9%	$4.87B	$1.24B	21.27	1,051	News Coverage Analyst Upgrade
DNTH Dianthus Therapeutics	3.0675 of 5 stars	$90.80 +3.7%	$117.82 +29.8%	+440.8%	$4.78B	$2.04M	N/A	80	Positive News Gap Down
ERAS Erasca	2.7544 of 5 stars	$15.05 -0.1%	$20.11 +33.6%	+1,123.3%	$4.69B	N/A	N/A	120	Trending News Gap Down
KNSA Kiniksa Pharmaceuticals International	3.1347 of 5 stars	$59.13 -0.6%	$60.86 +2.9%	+111.1%	$4.58B	$677.56M	65.70	220	Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:MPLT) was last updated on 6/29/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Maplight Therapeutics (MPLT) Competitors

MPLT vs. INDV, DNTH, ERAS, KNSA, and EWTX

How does Maplight Therapeutics compare to Indivior?

Summary

How does Maplight Therapeutics compare to Dianthus Therapeutics?

Summary

How does Maplight Therapeutics compare to Erasca?

Summary

How does Maplight Therapeutics compare to Kiniksa Pharmaceuticals International?

Summary

How does Maplight Therapeutics compare to Edgewise Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

MPLT vs. The Competition

Maplight Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Maplight Therapeutics (MPLT) Competitors

MPLT vs. INDV, DNTH, ERAS, KNSA, and EWTX

How does Maplight Therapeutics compare to Indivior?

Do insiders & institutionals believe in INDV or MPLT?

Do analysts prefer INDV or MPLT?

Does the media favor INDV or MPLT?

Which has better earnings and valuation, INDV or MPLT?

Is INDV or MPLT more profitable?

Summary

How does Maplight Therapeutics compare to Dianthus Therapeutics?

Which has better valuation & earnings, MPLT or DNTH?

Is MPLT or DNTH more profitable?

Do analysts prefer MPLT or DNTH?

Do institutionals & insiders have more ownership in MPLT or DNTH?

Does the media prefer MPLT or DNTH?

Summary

How does Maplight Therapeutics compare to Erasca?

Do insiders and institutionals hold more shares of ERAS or MPLT?

Does the media prefer ERAS or MPLT?

Do analysts recommend ERAS or MPLT?

Is ERAS or MPLT more profitable?

Which has stronger earnings and valuation, ERAS or MPLT?

Summary

How does Maplight Therapeutics compare to Kiniksa Pharmaceuticals International?

Which has preferable earnings and valuation, MPLT or KNSA?

Do insiders & institutionals have more ownership in MPLT or KNSA?

Do analysts recommend MPLT or KNSA?

Does the media refer more to MPLT or KNSA?

Is MPLT or KNSA more profitable?

Summary

How does Maplight Therapeutics compare to Edgewise Therapeutics?

Does the media prefer MPLT or EWTX?

Do analysts prefer MPLT or EWTX?

Is MPLT or EWTX more profitable?

Which has stronger valuation and earnings, MPLT or EWTX?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

MPLT vs. The Competition

Maplight Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools